GM
Live price temporarily unavailable.
Price history
Genmab A/s (GMAB) is a Health Care company. Latest news and coverage below.
IPO: July 18, 2019 · $17.75 offering · NASDAQ · View IPO details →
Genmab A/s revenue & net income history (FY2023–FY2025)
RevenueNet incomeNet margin (right axis, %)
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $2.39B | $3.12B | $3.72B |
| Growth (year over year) | — | +30.6% | +19.2% |
| Gross profit | $2.36B | $2.98B | $3.48B |
| Gross margin | 98.6% | 95.4% | 93.6% |
| Operating income | $772.0M | $972.0M | $1.06B |
| Operating margin | 32.3% | 31.1% | 28.6% |
| Net income | $631.0M | $1.13B | $963.0M |
| Net margin | 26.4% | 36.3% | 25.9% |
| EPS (diluted) | $9.58 | $17.53 | $15.37 |
| Balance sheet | |||
| Cash and equivalents | $2.20B | $1.38B | $1.72B |
| Total assets | $5.23B | $6.41B | $12.9B |
| Total liabilities | $545.0M | $1.28B | $7.03B |
| Shareholders' equity | $4.69B | $5.14B | $5.85B |
| Cash flow | |||
| Operating cash flow | $1.07B | $1.13B | $1.19B |
| Capital expenditure | $53.0M | $27.0M | $37.0M |
| Free cash flow | $1.02B | $1.10B | $1.15B |
| Share buybacks | $81.0M | $560.0M | $430.0M |
RevenueNet incomeNet margin (right axis, %)
| Q1 FY24†Mar 2024 | Q2 FY24Jun 2024 | Q4 FY24Dec 2024 | Q1 FY25†Mar 2025 | Q2 FY25Jun 2025 | Q4 FY25Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $603.0M | $779.0M | — | $715.0M | $925.0M | — |
| Growth (year over year) | — | — | — | +18.6% | +18.7% | — |
| Gross profit | $576.0M | $751.0M | — | $673.0M | $868.0M | — |
| Gross margin | 95.5% | 96.4% | — | 94.1% | 93.8% | — |
| Operating income | $116.0M | $236.0M | — | $188.0M | $360.0M | — |
| Operating margin | 19.2% | 30.3% | — | 26.3% | 38.9% | — |
| Net income | $192.0M | $203.0M | — | $195.0M | $336.0M | — |
| Net margin | 31.8% | 26.1% | — | 27.3% | 36.3% | — |
| EPS (diluted) | $2.92 | $3.13 | — | $3.03 | $5.42 | — |
| Balance sheet | ||||||
| Cash and equivalents | — | $622.0M | $1.38B | — | $1.30B | $1.72B |
| Total assets | — | — | $6.41B | — | $6.46B | $12.9B |
| Total liabilities | — | — | $1.28B | — | $1.16B | $7.03B |
| Shareholders' equity | — | $4.45B | $5.14B | — | $5.30B | $5.85B |
From Genmab A/s's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Genmab A/s
- Headquarters
- 1253 Copenhagen K, Denmark From SEC filings, Oct 2026
Recent News (3)
-
NeOnc among Names with 2026 Breakthroughs that Offer New Hope in the Fight Against Cancer NeOnc’s encouraging brain-cancer survival findings join 20206 developments from $RVMD, $MRNA, $MRK, $JNJ, $GMAB and $ABBV.
-
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?
-
Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab? Yahoo Finance
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International